Search

Displaying results 3981 - 3990 of 7456 in total
  1. Drug

    Selisistat

    go.drugbank.com/drugs/DB13978
    Investigational

    Selective inhibitor of SIRT1 that does not inhibit histone deacetylase (HDAC) or other sirtuin deacetylase family members (IC50 values are 98, 19600, 48700, > 100000 and > 100000 nM for SIRT1, SIRT2, SIRT3

  2. Drug

    GC-373

    go.drugbank.com/drugs/DB15797
    Experimental

    The results showed potent inhibition of the target, suggesting that GC-373 holds therapeutic potential for Covid-19[A219036].

    Categories: Experimental Unapproved Treatments for COVID-19
  3. Drug

    2-deoxyglucose

    go.drugbank.com/drugs/DB08831
    Investigational

    Although there are several possible therapeutic indications for 2-deoxyglucose, presently there is no approved indication for 2-deoxyglucose as a therapeutic agent. … 2-deoxyglucose is predominantly used as a diagnostic agent in its radiolabelled form (fluorine-18 is used as the radiolabel).

  4. Drug

    Human ciliary neurotrophic factor, recombinant (E. coli)

    go.drugbank.com/drugs/DB17959
    Experimental

    The trials were NCT03071965, an extension study of the NT-501 CNTF implant for macular telangiectasia, and NCT01949324, a Phase 2 multicenter randomized clinical trial of CNTF for macular telangiectasia … Human ciliary neurotrophic factor, recombinant was investigated for macular telangiectasia in two clinical trials.

  5. Drug

    Ferrous chloride

    go.drugbank.com/drugs/DB13569
    Investigational

    Mixtures: Nutritrace Concentrate for solution for infusion
  6. Drug

    Hydrotalcite

    go.drugbank.com/drugs/DB13322
    ApprovedInvestigationalWithdrawn

    Categories: Drugs for Acid Related Disorders
  7. Drug

    MDX-1379

    go.drugbank.com/drugs/DB05329
    Investigational

    MDX-1379 vaccine consists of two gp100 melanoma peptides. This drug is underinvestigation to treat malignant melanoma.

  8. Drug

    Lumefantrine co-artemether

    go.drugbank.com/drugs/DB13085
    ApprovedInvestigationalWithdrawn

    Lumefantrine Co-Artemether (Riamet) has been investigated for the treatment of Malaria, Malaria, Falciparum, Malaria in Pregnancy, Uncomplicated Malaria, and Uncomplicated Knowlesi Malaria. … The exact mechanism of action of lumefantrine is not well defined, but it is thought to inhibit -hematin formation, an important detoxification pathway for the parasite.

  9. Drug

    Paraldehyde

    go.drugbank.com/drugs/DB09117
    ApprovedWithdrawn

    Paraldehyde is used as an ingredient in some cough medicines as an expectorant, but its efficacy for this indication has not been confirmed and its use as an expectorant may possibly be due to a placebo

  10. Drug

    Glasdegib

    go.drugbank.com/drugs/DB11978
    ApprovedInvestigational

    [A40310] Glasdegib was developed by Pfizer Inc and approved on November 21, 2018 by the FDA for the treatment of Acute Myeloid Leukemia (AML). … [A258493] Aberrant of Hh signaling is one of the main pathophysiologies of AML, with observed overexpression or constitutive activation of SMO.